I'm initiating SELLAS Life Sciences (SLS) with a "Hold" rating. The reason why I'm giving this biotech this rating is because it is in the process of developing its WT1-targeting immunotherapeutic ...
SAN DIEGO and TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly ...
An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help ...
Patients were enrolled at the Peking University Institute of Hematology between July 2018 and November 2019. Human leukocyte antigen (HLA)-identical sibling donor (ISD) transplantation (6/6 matching ...
Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. With relapse rates as high as 50%, routine measurable residual disease (MRD) ...
Kura Oncology ((KURA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results